Under the contract, JCR will use its cell processing facility to develop JTR – 161 (DPC = dental pulp cells) for the treatment of acute cerebral infarction. JTR-161 stem cells are derived from dental pulp obtained from extracted teeth of healthy Japanese donors. The product will be administered intravenously to suitable patients (allogenic, probably MHC-tested) and is considered unlikely to cause immune reactions.

JCR news release June 18, 2017